Tara Conley, NP
Adult Health · Round Rock, TXNPI 1659662799
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 838 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 28.4% of the total. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 838 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Bristol Myers Squibb$813
- Pfizer$444
- Celltrion USA Inc.$401
- plus $4K from 29 others
What the payments were for
- Consulting fees$1,2459%
- Food & beverage$12,99891%
- Education$540%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 232 | $4,065 |
| Johnson & Johnson(2 entities) | 88 | $2,667 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 211 | $2,146 |
| Bristol Myers Squibb | 52 | $813 |
| Pfizer | 34 | $444 |
| Celltrion USA Inc. | 27 | $401 |
| Sanofi | 15 | $388 |
| Aimmune Therapeutics, Inc. | 28 | $309 |
| Daiichi Sankyo Inc. | 16 | $291 |
| Lilly USA, LLC | 12 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $263 |
| Redhill Biopharma Inc. | 29 | $261 |
| QOL Medical, LLC | 15 | $242 |
| Nestle Healthcare Nutrition Inc. | 4 | $210 |
| Ardelyx, Inc. | 7 | $133 |
| Phathom Pharmaceuticals, Inc. | 1 | $127 |
| Regeneron Healthcare Solutions, Inc. | 4 | $126 |
| Janssen Scientific Affairs, LLC | 2 | $120 |
| Ironwood Pharmaceuticals, Inc | 7 | $116 |
| Intercept Pharmaceuticals, Inc. | 8 | $109 |
| Axonics, Inc. | 1 | $103 |
| Merck | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 1 | $93 |
| Madrigal Pharmaceuticals | 4 | $92 |
| Gilead | 5 | $90 |
| Ipsen Biopharmaceuticals, Inc | 3 | $64 |
| Braintree Laboratories, Inc. | 4 | $56 |
| UCB, Inc. | 2 | $34 |
| Pharmacosmos Therapeutics Inc. | 2 | $33 |
| Exact Sciences | 1 | $31 |
| Enterra Medical, Inc. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| Organon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,297 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 16 | $37,340 |
| LinzessLinaclotide | 28 | $26,040 |
| TrulancePlecanatide | 15 | $23,096 |
| Dexlansoprazole DrDexlansoprazole | 27 | $5,642 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 26 | $4,441 |
| Colesevelam Hcl | 13 | $2,527 |
| Pantoprazole Sodium | 125 | $1,815 |
| Dicyclomine Hcl | 70 | $1,426 |
| Lubiprostone | 14 | $1,321 |
| Famotidine | 80 | $1,109 |
| Omeprazole | 81 | $938 |
| Sucralfate | 13 | $574 |
| Ondansetron OdtOndansetron | 32 | $307 |
| Nortriptyline Hcl | 15 | $265 |
| Buspirone Hcl | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,146 | $60,43631 claims |
| AbbVieLinzess | $4,065 | $26,04028 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $20 | $4,44126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Round Rock
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.